Research

(Selected Recent Publications cited > 100 times are in bold)

  1. Coward, J.K., Motola, N.C. and Moyer, J.D. Polyamine biosynthesis in rat prostate.  Substrate inhibition properties of 7-deaza analogues of decarboxylated S-adenosylmethionine and 5’-methylthioadenosine.  J. Med. Chem. 20: 500-505, 1977.
  2. Handschumacher, R.E., Schwartz, P.M. and Moyer, J.D.: Some consequences of inhibition of the De Novo pathway of pyrimidine biosynthesis.  In:  Antimetabolites in Biochemistry, Biology and Medicine.  Skoda, J. and P. Langen (Eds.),England, Pergamon Press, 1979, pp. 297-303.
  3. Moyer, J.D. and Handschumacher, R.E. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.  Cancer Res. 39: 3089-3094, 1979.
  4. Dix, D.E., Lehman, C.P., Jakubowski, A., Moyer, J.D. and Handschumacher, R.E.  Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells. Cancer Res. 39: 4485-4490, 1979.
  5. Gasser, T., Moyer, J.D. and Handschumacher, R.E. Novel single-pass exchange of circulating uridine in rat liver.  Science 213: 777-778, 1981.
  6. Moyer, J.D., Oliver, J.T. and Handschumacher, R.E. Salvage of circulating pyrimidine nucleosides in the rat.  Cancer Res. 41: 3010-3017, 1981.
  7. Moyer, J.D., Smith, P.A., Levy, E.J. and Handschumacher, R.E.  Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.  Cancer Res. 42: 4525-4531, 1982.
  8. Moyer, J.D. and Henderson, J.F. The nucleoside triphosphate specificity of firefly luciferase.  Anal. Biochem. 131: 187-189, 1983.
  9. Moyer, J.D., Henderson, J.F. and von Tigerstrom, R. Ultrasensitive assay for RNA:  Application to 100-500 cells.  Anal. Biochem. 131:190-193, 1983.
  10. Moyer, J.D. and Henderson, J.F. Biochemical measurements of microscopic cell colonies.  Nucleoside triphosphate pools.  Biochem. Pharmacol. 32: 3831-3834, 1983.
  11. Moyer, J.D. and Henderson, J.F. Salvage of circulating hypoxanthine in the mouse.  Can. J. Biochem. 61: 1153-1157, 1983.
  12. Moyer, J.D. and Paterson, A. R. P. and Henderson, J.F. Effect of a nucleoside transport inhibitor on the disposition of uridine in mice.  Biochem. Pharmacol. 33: 2327-2328, 1984.
  13. Lim, M., Moyer, J.D., Cysyk, R.L., and Marquez, V.E. Cyclopentenyl uridine and cytidine analogs as inhibitors of uridine-cytidine kinase.  J. Med. Chem. 27: 1536-1538, 1984.
  14. Moyer, J.D. and Henderson, J.F. Salvage of uridine in the mouse. The effect of uridine phosphorylase pretreatment.  Biochem. Pharmacol. 34: 101-105, 1985.
  15. Moyer, J.D., Malinowski, N., and Ayers, O.  Salvage of circulating pyrimidine nucleosides by tissues of the mouse.  J. Biol. Chem. 260: 2812-2818, 1985.
  16. Moyer, J.D., Karle, J.M., Malinowski, N., Marquez, V.E., Salam, M.A., Malspeis, L. and Cysyk, R.L.  Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.  Mol. Pharmacol. 28: 454-460, 1985.
  17. Moyer, J.D. and Henderson, J.F. Compartmentation of intracellular nucleotides in mammalian cells.  Crit. Rev. Biochem.  19:  45-61, 1985.
  18. Moyer, J.D., Malinowski, M., and Cysyk, R.L.  The effect of 3-deazauridine and dipyridamole on uridine utilization by mice.  Eur. J. Cancer Clin. Oncol.  22: 323-327, 1986.
  19. Moyer, J.D., Malinowski, N., Treanor, S., and Marquez, V.E. Antitumor activity and biochemical effects of cyclopentenyl cytosine.  Cancer Res. 46: 3325-3329, 1986.
  20. Dean, N.M. and Moyer, J.D.  Separation of multiple isomers of inositol phosphates formed in GH3 cells.  Biochem. J. 242: 361-367, 1987.
  21. Jiang, C., Moyer, J.D., and Baker, D.C.  Synthesis of deoxy and deoxyhalogeno analogs of myo-inositol.  J. Carbohydrate Chem. 6: 319-355, 1987.
  22. Cunha-Melo, J.R., Dean, N., Moyer, J., Maeyama, K., and Beaven, M.A.  The kinetics of phosphoinositide hydrolysis in rat basophilic leukemia (RBL- 2H3) cells varies with the type of IgE receptor cross-linking agent used.  J. Biol. Chem. 262: 1145-1163, 1987.
  23. Moyer, J.D., Reizes, O., Dean, N.M., and Malinowski, N. D-myo-inositol (1,4)-bisphosphate 1-phosphatase.  Partial purification from rat liver and characterization.  Biochem. Biophys. Res. Comm.  146:  1018-1026, 1987.
  24. Dean, N.M. and Moyer, J.D.  Metabolism of inositol bis-tris-, tetrakis-, and pentakisphosphates in GH3 Cells. Biochem. J. 250: 493-500, 1988.
  25. Moyer, J.D., Malinowski, N., Napier, E., and Strong, J. Uptake and metabolism of myo-inositol by L1210 leukemia cells.  Biochem. J. 254: 95-100, 1988.
  26. Moyer, J.D., Reizes, O., Malinowski, N., Ahir, S. Jiang, C., and Baker, D.C.  Substrate properties of analogs of myo-inositol.  Mol. Pharm. 33: 683-689, 1988.
  27. Moyer, J.D.  Inhibition of growth factor action as an approach to cancer chemotherapy.  In: Developments in Cancer Chemotherapy, Glazer, R. (ed.) CRC Press, pp. 25-40, 1988.
  28. Sausville, E.A., Moyer, J.D., Heikkila, R., Neckers, L.M., and Trepel, J.B.  A correlation of bombesin-responsiveness with myo-family gene expression in small cell lung carcinoma cell lines.  Ann. N.Y. Acad. Sci.  547: 310-321, 1988.
  29. Trepel, J.B., Moyer, J.D., Heikkla, R., and Sausville, E.A.  Modulation of bombesin-induced phosphatidylinositol hydrolysis in a small cell lung cancer cell line.  Biochem. J.  255: 403-410, 1988.
  30. Trepel, J.B., Moyer, J.D., Cuttitta, F., Frucht, H., Coy, D.H., Natale, R.B., Mulshine, J.L., Jensen, R.T., and Sausville, E.  A novel bombesin receptor antagonist inhibits autocrine signal transduction in a small cell lung carcinoma cell line.  Biochem. Biophys. Res. Commun.  156: 1383-1389, 1988.
  31. Moyer, J.D., Reizes, O., Malinowski, N., Jiang, C., and Baker, D.C.  Fluorinated analogues of myo-inositols as biological probes of phosphatidylinositol metabolism.  In: Fluorinated Carbohydrates:  Chemical and Biochemical Aspects, N.R. Taylor, Ed., Am. Chem. Soc., 1988.
  32. Kang, G.J., Cooney, D.A., Moyer, J.D., Kelley, J.A., Kim, H-Y., Marquez, V.E., and Johns, J.G.  Cyclopentenyl cytosine triphosphate.  Formation and inhibition of CTP synthetase.  J. Biol. Chem. 264:  713-718, 1989.
  33. Cushman, M., Jarayj, J. and Moyer, J.D.  Synthesis, biological testing,and stereochemical assignment of an end group modified retro-inverso bombesin C-terminal nonapeptide  J. Org. Chem. 55: 3186-3194, 1990.
  34. Moyer, J.D. and Fischer, P. H.  The Promise of Oncogene Inhibitors as Novel Antitumor Agents  In:  Cancer Chemotherapy,   John Hickman and T. Tritton Eds., 1993.
  35. O'Dwyer, P. J., Moyer, J.D., Suffness, M., Harrison, S.D., Cysyk, R., Hamilton, T.C., and Plowman, J.  Antitumor activity and biochemical effects of aphidicolin glycinate (NSC303812) alone and in combination with cisplatin in vivo.  Cancer Res. 54: 724-729, 1994.
  36. Miller, P., Schnur, R.C., Barbacci, E., Moyer, M.P., and Moyer, J.D.  Binding of Benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem. Biophys. Res. Commun.  201: 1313-1319, 1994.
  37. Miller, P., DiOrio, C., Moyer, M., Schnur, R.C., Bruskin, A., Cullen, W., and Moyer, J.D.  Depletion of the erbB2 gene product p185 by benzoquinoid ansamycins.  Cancer Res. 54: 2724-2730, 1994.
  38. Barbacci, E., Guarino, B., Stroh, J., Singleton, D., Rosnack, K., Moyer, J. D., and Andrews, G.  The structural basis for the selectivity of EGF and Heregulin binding. J. Biol. Chem. 270: 9585-9589, 1995.
  39. Cysyk, R.L., Malinowski, N., Marquez, V., Zaharavitz, D., August, E.M., and Moyer, J.D.  Cyclopentenyl Uracil: an effective inhibitor of uridine salvage in vivo.  Biochem. Pharm.  49: 203-207, 1995.
  40. Schnur, R.C., Corman, M., J.D. Moyer et. al. erbB2 Oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships.  J. Med. Chem.  38: 3813-3820, 1995.
  41. Schnur, R.C., Corman, M.C., Moyer J.D. et al. Inhibition of the oncogene product p185erbB2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.  J. Med. Chem. 38: 3806-3812, 1995.
  42. Chavany, C., Mimnaugh, E., Miller, P., Bitton, R., Nguyen, P., Trepel, J., Whitesell, L., Schnur, R., Moyer, J., and Neckers, L.   P185erbB2 binds to GRP94 in vivo: Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2   J. Biol. Chem. 271: 4974-4977, 1996.
  43. Tzahar, E. Pinkas-Kamarski, R., Moyer, J.D.,  et al. Bivalency of EGF-like ligands drives the erbB signalling network. EMBO 16: 4938-4950, 1997.
  44. Moyer, J.D., Barbacci, E.G., Iwata, K.K. et.al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57: 4834-4848, 1997.
  45. Tzahar, E.,. Moyer J.D., et al. Pathogenic pox viruses reveal viral strategies to exploit the erbB signalling network. EMBO J 17: 5948, 1998.
  46. Pinkas-Kamarski, R., Shelly, M., Guarino, B.C., Wang, L.M., Lyass, L., Alroy, I., Alimandi, M., Kuo, A., Moyer, J. D., Lavi, S., Eisenstein, M., Ratzkin, B. J. Seger, R., Bacus, S. S., Pierce, J. H., Andrews, G. C., and  Yarden, Y.  ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Molecular and Cellular Biology 18: 7602, 1998.
  47. Baker, D.C., Johnson, S.C., Moyer, J.D., Malinowski, N., Tagliaferri, F., and Tuinman, A. 5-Deoxy-5-fluoro-1-O-phosphatidylinositol: Evidence for the enzymatic incorporation of a fraudulent cyclitol into the phosphatidylinositol cycle: A mass spectrometry study. In: Phosphoinositides K.S. Bruzik Ed., ACS Symposium Series Vol 718, Oxford Univ. Press 1999.
  48. Pollack, V., Savage, D., Baker, D., Tsaparikos, K., Sloan, D., Moyer, J., Barbacci, E., Pustilnik, L., Smolarek, T., Davis, J., Vaidya, M., Arnold, L., Doty, J., Iwata, K., and Morin, M. Inhibition of epidermal growth factor receptor-associated phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in nude mice. J. Pharmacol. Exper. Therapeutics 291: 739-748, 1999.
  49. Cohen, L.A., Pittman, B., Wang, C.X., Aliaga, C., Yi, L, and Moyer, J.D. Lasofoxifene, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitrosourea (NMU)-induced rat mammary tumor model. Cancer Research 61: 8683-8688, 2001.
  50. Bhattacharya,S.K.,  Cox, E.D., Kath, J.C., Mathiowetz, A.M.,  Morris, J., Moyer, J.D.,. Pustilnik, L.R., Rafidi, K., Richter, D.T, Su, C. and Wessel, M.D..  Achieving selectivity between highly homologous tyrosine kinases: A novel selective erbB2 inhibitor. Biochem. Biophys. Res. Commun. 307: 267-273, 2003.
  51. Barbacci, E.B.,  Cox, D.E., Emerson, E., Iwata, K., Jani, J., Kath, J.C., Miller, P.E., Moyer, J.D., Pustilnik, L.R., and Rossi, A.   The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Research 63: 4450-4459, 2003.
  52. Changellian, P. et al. (Moyer) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302:875, 2003
  53. Cohen, B.D., Baker, D.A., Soderstrom, C., Tkalcevic, G.,  Rossi, A., Miller, P.E., Tengowski, M.W., Wang, F. , Gualberto, A., Beebe, J.S., and Moyer, J.D. Combination therapy enhances the inhibition of tumor growth with the fully human anti-IGF-1R monoclonal antibody CP-751,871.  Clinical Cancer Res. 11: 2063-2073, 2005.
  54. Parkinson, T., Howett, M.K., Welsh, P.A., Patrick, S.D., Neely, E.B., Flanagan, N., Pollack, V.A. Pustilnik, L.R., Moyer, J.,  Perros, M. An inhibitor of the epidermal growth factor receptor function does not affect the ability of human papillomavirus 11 to form warts in the xenografted immunodeficient mouse model. Antiviral Research 74: 43-50, 2007.
  55. Lippa, B, Kauffman, G.S.,  Arcari, J., Kwan, T., Chen, J., Hungerford, W., Bhattacharya, S., Zhao, X., Williams, C.,  Xiao, J., Pustilnik, L., Su, C., Moyer, J.D., Ma, L., Campbell, M., Steyn, S. 2007 The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.  Bioorganic & Medicinal Chemistry Letters  17:3081-3085.
  56. Jani, J. P.; Finn, R. S.; Campbell, M.; Coleman, K. G.; Connell, R. D.; Currier,  N.; Emerson, E.O.; Floyd, E.; Harriman, S.; Kath, J. C.; Morris, J.; Moyer, J. D.;  Pustilnik, L. R.; Rafidi, K.;  Rossi, A. M. K.;  Steyn, S. J.; Wagner, L.; Winter, S. M.; and S. K. Bhattacharya (2007). Discovery and Pharmacological Characterization of CP-724,714, a Selective erbB2 Tyrosine Kinase Inhibitor Cancer Res. 66:9887-9893.
  57. Jitesh P. Jani, Joel Arcari, Vincent Bernardo, Samit K. Bhattacharya, David Briere, Bruce D. Cohen, Kevin Coleman, James G. Christensen, Erling O. Emerson, Amy Jakowski, Kenneth Hook, Gerrit Los, James D. Moyer, Ingrid Pruimboom-Brees,Leslie Pustilnik, Ann Marie Rossi, Stefan J. Steyn, Chunyan Su, Konstantinos Tsaparikos, Donn Wishka, Kwansik Yoon, John L. Jakubczak PF-3814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy  (2010) Mol Cancer Ther.  9:883-894, 2010.

Patents and Published Patent Applications

  1. Norris, T, Raggon, J.W., Connell, R.D., Moyer, J.D., Morin, M.J., Kajiji, S.M., Foster, B.A., Ferrante, K.J., Silberman, S.L. Stable polymorph of N-(3-ethylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof. US6900221 (2005).
  2. Cohen, B.D., Beebe, J, Miller, P.E., Moyer, J.D., Corvalan, J.R., Gallo, M. Antibodies to Insulin-like Growth Factor I Receptor. US7037498 (2006). 
  3. Norris, T, Raggon, J.W., Connell, R.D., Moyer, J.D., Morin, M.J., Kajiji, S.M., Foster, B.A., Ferrante, K.J., Silberman, S.L. Treating abnormal cell growth with a Stable polymorph of N-(3-ethylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride US7087613 (2006).
  4. Miller, P.E. and Moyer, J.D. Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor. US20020061304 A1.
  5. Connell, R.D., Kath, J.C., Moyer, J.D. Small molecules for the treatment of abnormal cell growth. US20030171386 A1. (2006).
  6. Kath, J.C., Moyer, J.D., Connell, R.D. Quinazoline derivatives for the treatment of abnormal cell growth. WO2003049740.
  7. Bhattacharya, S. K., Connell, R. D., Moyer, J. D., Jani, J.P., Noe, D.A., Steyn, S.J..   Dosing schedule for erbB2 anticancer agents.   WO  2005016347 (2005).